{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-077030","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2023-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.950563+00:00","generated_at":"2026-06-10T16:28:17.934751+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Hoth Therapeutics raises $2.89M via 1.1M shares and warrants at $2.63/share","bullets":["Gross proceeds ~$2.89M from sale of 1,100,000 shares (or equivalents) and concurrent private placement of warrants.","Warrants exercisable at $2.505/share for five years; issued to investors and placement agent (H.C. Wainwright).","Placement agent fees: 7% cash fee plus 1% management fee and 55,000 placement agent warrants at $3.2875.","Offering closed September 15, 2023; net proceeds for working capital and general corporate purposes.","Shares offered under existing S-3 shelf registration; warrants unregistered under Section 4(a)(2) and Regulation D."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-077030","json":"https://secwatch.observer/filing/0001213900-23-077030.json","markdown":"https://secwatch.observer/filing/0001213900-23-077030.md","text":"https://secwatch.observer/filing/0001213900-23-077030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023077030/0001213900-23-077030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023077030/ea185246-8k_hoththera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T16:28:17.934751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e03924b0998c63769e25e9c0be87bbd90ace691d","claim":"Hoth Therapeutics, Inc. entered into Purchase Agreement with certain institutional investors valued at $2.89 million (effective 2023-09-13).","evidence_excerpt":"On September 13, 2023, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 549,275 shares (the “Shares”) of common stock of the Company (the “Common Stock”), pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 550,725 shares of Common Stock of the Company (the “Pre-Funded Warrant Shares”), having an exercise price of $0.001 per share, at a purchase price of $2.63 per share of Common Stock and a purchase price of $2.629 per Pre-Funded Warrant (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390023077030/0001213900-23-077030-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"$2.89 million"},{"label":"Effective","value":"2023-09-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}